- Report
- March 2024
- 92 Pages
Europe
From €2455EUR$2,485USD£2,044GBP
€3508EUR$3,550USD£2,920GBP
- Report
- March 2024
- 79 Pages
North America
From €2455EUR$2,485USD£2,044GBP
€3508EUR$3,550USD£2,920GBP
- Report
- March 2024
- 79 Pages
Middle East, Africa
From €2455EUR$2,485USD£2,044GBP
€3508EUR$3,550USD£2,920GBP
- Report
- March 2024
- 118 Pages
Asia Pacific
From €2455EUR$2,485USD£2,044GBP
€3508EUR$3,550USD£2,920GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €3424EUR$3,465USD£2,850GBP
€4891EUR$4,950USD£4,071GBP
- Report
- November 2024
Global
From €300EUR$325USD£258GBP
- Report
- May 2022
- 510 Pages
Global
From €2964EUR$3,000USD£2,467GBP
- Report
- December 2020
- 120 Pages
Global
From €1976EUR$2,000USD£1,645GBP
- Report
- December 2022
- 153 Pages
Global
From €5187EUR$5,250USD£4,318GBP
- Report
- August 2023
- 240 Pages
Global
From €1966EUR$1,990USD£1,637GBP
- Report
- March 2022
- 175 Pages
Global
From €1966EUR$1,990USD£1,637GBP
- Report
- September 2024
- 150 Pages
China
From €5879EUR$5,950USD£4,893GBP
- Report
- November 2020
- 49 Pages
Global
€1302EUR$1,318USD£1,084GBP
- Drug Pipelines
- September 2019
- 118 Pages
Global
€9881EUR$10,000USD£8,224GBP
- Report
- August 2018
- 16 Pages
Global
From €9881EUR$10,000USD£8,224GBP
- Report
- August 2018
- 25 Pages
Global
From €9881EUR$10,000USD£8,224GBP
- Report
- August 2018
- 48 Pages
Global
From €9881EUR$10,000USD£8,224GBP
- Report
- August 2018
- 21 Pages
Global
From €9881EUR$10,000USD£8,224GBP
- Drug Pipelines
- August 2018
- 37 Pages
Global
From €9881EUR$10,000USD£8,224GBP
- Report
- September 2021
- 40 Pages
China
From €2569EUR$2,600USD£2,138GBP
The Lung Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat lung cancer. These drugs are used to treat both non-small cell and small cell lung cancer, the two most common types of lung cancer. The drugs are designed to target the cancer cells and stop them from growing and spreading. Common treatments include chemotherapy, targeted therapy, immunotherapy, and radiation therapy.
The Lung Cancer Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies such as Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, and Roche are all major players in the market. These companies are constantly researching and developing new drugs to treat lung cancer, as well as improving existing treatments.
In addition, there are many smaller companies that specialize in the development of new drugs for the treatment of lung cancer. These companies often collaborate with larger pharmaceutical companies to bring their drugs to market. Examples of these companies include ImmunoGen, Inc., Oncolytics Biotech, and ImmunoCellular Therapeutics. Show Less Read more